S&P Futures
3,812.25 -15.00 (-0.39%) Dow Futures
30,948.00 -113.00 (-0.36%) Nasdaq Futures
11,560.25 -51.00 (-0.44%) Russell 2000 Futures
1,719.30 -9.20 (-0.53%) Crude Oil
110.30 +1.87 (+1.72%) Gold
1,807.40 +5.90 (+0.33%)
Outlook Therapeutics, Inc. (OTLK)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0200 |
| Open | 1.0200 |
| Bid | 1.0000 x 2900 |
| Ask | 1.0500 x 4000 |
| Day's Range | 1.0000 - 1.0500 |
| 52 Week Range | 0.6840 - 3.2700 |
| Volume | |
| Avg. Volume | 1,083,653 |
| Market Cap | 230.989M |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings Date | Feb 14, 2022 - Feb 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.17 |
- GlobeNewswire
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010
Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug Administration (FDA) ISELIN, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, is providing an update on its Biologics License Application (BLA) submi
- GlobeNewswire
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
ISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that the U.S. Food and Drug Administration (FDA) has requested additional information in order to complete the filing of the Company’s Biologics License Application (BLA) for ONS-5010/ LYTENAVA™ (bevacizumab-vikg) for the treatm
- Simply Wall St.
Bullish Outlook Therapeutics, Inc. (NASDAQ:OTLK) insiders filled their treasuries with US$557k worth of stock over last year
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
